The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups
- PMID: 18621562
- DOI: 10.1016/j.ijid.2008.02.013
The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups
Abstract
Objective: To measure the impact of invasive aspergillosis infection on US hospital costs and financial performance across different patient populations.
Methods: Hospital discharge data for patients with a primary or secondary diagnosis of aspergillosis were extracted from the 2003 Nationwide Inpatient Sample (NIS) and the fiscal year 2003 (FYO3) Medicare Provider Analysis and Review (MedPAR) file. The data on patient demographics, length of stay (LOS), hospital charges, estimated costs, and reimbursement levels were reported. After controlling for comorbidities, operative procedures, and diagnosis-related group (DRG) assignment, the clinical and economic outcomes were compared for patients with and without aspergillosis.
Results: The NIS contains a total of over 38 million projected hospital discharges. From these, 10400 aspergillosis cases were identified across 171 DRGs, resulting in a US incidence rate of 36 per million per year. The mean age of aspergillosis patients was 55.6 years, with 53.4% male and 67.9% Caucasian. The median (mean) LOS per aspergillosis patient was 10 (17.7) days, with a median (mean) total hospital charge (THC) of $44,845 ($96,731). Among the patient subgroups analyzed, the median (mean) THC per patient ranged from $47,252 ($82,946) for HIV to $413,200 ($442,233) for bone marrow transplant (BMT). When compared to the non-aspergillosis patient population, the data showed a significant increase in LOS, THC, and hospital costs. Furthermore, the higher hospital costs associated with aspergillosis patients were not matched by similar increases in reimbursements, resulting in a greater financial loss for hospitals. The mean reimbursement-to-cost ratio for aspergillosis cases across the DRGs analyzed was 0.80.
Conclusions: Aspergillosis affects a wide range of patient groups and has a negative economic impact across many DRGs. Improved prevention, diagnosis, and patient management strategies can help mitigate these effects on hospital financial performance.
Comment in
-
The economic impact of invasive aspergillosis in intensive care unit patients.Int J Infect Dis. 2010 Jun;14(6):e536-7. doi: 10.1016/j.ijid.2009.06.014. Epub 2009 Aug 26. Int J Infect Dis. 2010. PMID: 19713140 No abstract available.
Similar articles
-
Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.Curr Med Res Opin. 2009 Sep;25(9):2151-7. doi: 10.1185/03007990903102743. Curr Med Res Opin. 2009. PMID: 19601711
-
Do older Medicare patients cost hospitals more? Evidence from an academic medical center.Arch Intern Med. 1993 Jan 11;153(1):89-96. Arch Intern Med. 1993. PMID: 8422203
-
Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000.Pediatrics. 2006 Apr;117(4):e711-6. doi: 10.1542/peds.2005-1161. Epub 2006 Mar 13. Pediatrics. 2006. PMID: 16533892
-
Impact of DRGs on the medical profession.Clin Lab Sci. 1993 May-Jun;6(3):183-5. Clin Lab Sci. 1993. PMID: 10146219 Review.
-
Acute care costs of the oldest old.Hosp Pract (1995). 1997 Jul 15;32(7):123-4, 129-32, 137. doi: 10.1080/21548331.1997.11443529. Hosp Pract (1995). 1997. PMID: 9227662 Review.
Cited by
-
Microbiomes Detected by Bronchoalveolar Lavage Fluid Metagenomic Next-Generation Sequencing among HIV-Infected and Uninfected Patients with Pulmonary Infection.Microbiol Spectr. 2023 Aug 17;11(4):e0000523. doi: 10.1128/spectrum.00005-23. Epub 2023 Jul 12. Microbiol Spectr. 2023. PMID: 37436163 Free PMC article.
-
Quantifying Deaths from Aspergillosis in HIV Positive People.J Fungi (Basel). 2022 Oct 27;8(11):1131. doi: 10.3390/jof8111131. J Fungi (Basel). 2022. PMID: 36354898 Free PMC article. Review.
-
Economic Burden of Fungal Diseases in the United States.Open Forum Infect Dis. 2022 Mar 23;9(4):ofac097. doi: 10.1093/ofid/ofac097. eCollection 2022 Apr. Open Forum Infect Dis. 2022. PMID: 35350173 Free PMC article.
-
A Rare and Potentially Catastrophic Infection: Primary Intestinal Aspergillosis-Case Report in an HIV Patient.Case Rep Infect Dis. 2018 Jul 8;2018:3269847. doi: 10.1155/2018/3269847. eCollection 2018. Case Rep Infect Dis. 2018. PMID: 30073099 Free PMC article.
-
Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis.Adv Ther. 2017 Jan;34(1):207-220. doi: 10.1007/s12325-016-0443-1. Epub 2016 Dec 2. Adv Ther. 2017. PMID: 27913989 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
